Guobang Pharmaceutical announced that its revenue for the first half of 2026 was 3.142 billion yuan, an increase of 3.84% over the previous year. Net profit attributable to shareholders of listed companies was 341 million yuan, down 25.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 321 million yuan, down 26.46% year on year.
智通財經·07/31/2026 09:49:19
語音播報
Guobang Pharmaceutical announced that its revenue for the first half of 2026 was 3.142 billion yuan, an increase of 3.84% over the previous year. Net profit attributable to shareholders of listed companies was 341 million yuan, down 25.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 321 million yuan, down 26.46% year on year.